期刊文献+

氯吡格雷抵抗基因多态性的研究进展 被引量:2

The Research Progress of Genetic Polymorphism in Clopidogrel Resistance
下载PDF
导出
摘要 氯吡格雷是临床上广泛使用的抗血小板药物,其对血小板的抑制具有个体差异性,部分患者在服用常规剂量氯吡格雷后存在抵抗现象而仍有缺血事件的发生,因此明确抵抗的机制将使患者受益。氯吡格雷抵抗可能受多方面因素的影响,目前认为基因多态性是一个重要原因。该文主要从氯吡格雷的吸收、活化和作用受体三方面的基因多态性进行综述。 Clopidogrel is an antiplatelet drug widely used in clinical practice. However, clopidogrel- induced platelet-inhibition is patient-specific. Ischemic events still occur when clopidogrel resistance exists in some patients taking standard dose clopidogrel therapy. Therefore, to clarify the mechanism of resistance will be beneficial to patients. The mechanisms of clopidogrel resistance are affected by multiple factors. It is considered that genetic polymorphism is one of the most important reasons. Here is to make a review of the genetic polymorohism from the apects of clopidogrel absorption, activation and functionin, receptors.
作者 陈菲 姚依群
出处 《医学综述》 2014年第9期1635-1638,共4页 Medical Recapitulate
关键词 氯吡格雷 氯吡格雷抵抗 基因多态性 Clopidogrel Clopidogrel resistance Genetic polymorphism
  • 相关文献

参考文献27

  • 1CAPRIE Steering Committee.A randomised,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE)[J].Lancet,1996,348(9038):1329-1339.
  • 2Mehta SR,Yusuf S.The Clopidogrel in Unstable angina to prevent Recurrent Events(CURE)trial programme;rationale,design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease[J].Eur Heart J,2000,21(24):2033-2041.
  • 3Chen ZM,Jiang LX,Chen YP,et al.Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomized placebo-controlled trial[J].Lancet,2005,366(9497):1607-1621.
  • 4Stephen D,Wiviott,MD.Clopidogrel resisance a new chapter in a fast-moving story[J].Circulation,2004,109(25):3064-3067.
  • 5Cairns JA,Eikelboom J.Clopidogrel resistance:more grist for the mill[J].Am Coll Cardiol,2008,51(20):1935-1937.
  • 6Kazui M,Nishiya Y,Ishizuka T,et al.Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
  • 7Muller I,Besta F,Schulz C,et al.Effects of statins on platelet inhibition by a high loadingdose of clopidogrel[J].Circulation,2003,108(18):2195-2197.
  • 8Barragan P,Bouvier JL,Roqu ebert PO,et al.Resistance tothienopyridines:clinical detection of coronary stent thrombosis bymonitoring of vasodilator stimulated phosphoprot einphosphorylation[J].Catheter Cardiovasc Interv,2003,59(3):295-302.
  • 9Bliden KP,DiChiara J,Tantry US,et al.Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:is the current antiplatelet therapy adequate?[J].J Am Coll Cardio,2007,49(6):657-666.
  • 10Lau WC,Gurbel PA,Watkins PB,et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance[J].Circulation,2004,109(2):166-171.

同被引文献19

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部